FIELD: medicine.
SUBSTANCE: invention refers to medicine and concerns methods of neural disorder treatment with introducing hematopoietic growth factors. Substance of the invention includes G-CSF or its functionally active version 90% identical to human G-CSF sequence presented in SEQ ID NO:28 to be applied in therapy of amyotrophic lateral sclerosis.
EFFECT: benefit of the invention consists in neuroprotection of disease-related nerve cells.
2 cl, 38 ex, 1 tbl, 41 dwg
| Title | Year | Author | Number |
|---|---|---|---|
| PRODUCTION OF GABA-ergic NEURONS in vitro OF EMBRYO STEM CELLS AND APPLICATION THEREOF IN TREATING NEURAL DISORDERS | 2004 |
|
RU2380410C2 |
| NEW APPLICATION | 2004 |
|
RU2416426C2 |
| PRODUCTION OF TERMINAL-DIFFERENTIATED DOFAMINNERGIC NEURONES FROM EMBRIONIC HUMAN FOUNDER CELLS | 2004 |
|
RU2345133C2 |
| INHIBITORS OF SIGNAL TRANSMISSION OF TRANSFORMING GROWTH FACTORS (TGF-R) FOR TREATMENT OF CNS DISORDERS | 2005 |
|
RU2385933C2 |
| USING MESENCHYMAL AND NEURONAL MARKER EXPRESSING STEM CELLS AND THEIR COMPOSITIONS FOR TREATING NEUROLOGICAL DISEASES (VERSIONS) | 2017 |
|
RU2742828C2 |
| STEM CELLS EXPRESSING MESENCHYMAL AND NEURONAL MARKERS, COMPOSITIONS THEREOF AND METHODS OF PRODUCING SAID MESENCHYMAL AND NEURONAL MARKERS | 2017 |
|
RU2741839C2 |
| NOOTROPIC COMPOSITION BASED ON POLYPEPTIDE COMPLEXES ISOLATED FROM NEURONS AND GLIAL CELLS OBTAINED BY DIRECTED DIFFERENTIATION OF INDUCED HUMAN PLURIPOTENT STEM CELLS | 2018 |
|
RU2690846C1 |
| TREATMENT OF NEUROLOGICAL DYSFUNCTION BY USING FRUCTOPYRANOSE AND ERYTHROPOIETIN SULFAMATES | 2002 |
|
RU2317086C2 |
| COMPOSITION FOR NEUROPROTECTION AND STIMULATION OF BRAIN NEUROREGENERATION AFTER INJURY, AGENT BASED ON IT, A METHOD OF ITS PRODUCTION AND USE | 2022 |
|
RU2803286C1 |
| METHOD FOR PREPARING A NOOTROPIC COMPOSITION BASED ON POLYPEPTIDE COMPLEXES ISOLATED FROM NEURONS AND GLIAL CELLS OBTAINED BY DIRECTIONAL DIFFERENTIATION OF INDUCED HUMAN PLURIPOTENT STEM CELLS | 2018 |
|
RU2690498C1 |
